156 related articles for article (PubMed ID: 38267353)
21. Efficacy and Toxicity of CD19 Chimeric Antigen Receptor T Cell Therapy for Lymphoma in Solid Organ Transplant Recipients: A Systematic Review and Meta-Analysis.
Yamshon S; Gribbin C; Chen Z; Demetres M; Pasciolla M; Alhomoud M; Martin P; Shore T
Transplant Cell Ther; 2024 Jan; 30(1):73.e1-73.e12. PubMed ID: 37279856
[TBL] [Abstract][Full Text] [Related]
22. Neurotoxicity and management of primary and secondary central nervous system lymphoma after adoptive immunotherapy with CD19-directed chimeric antigen receptor T-cells.
Karschnia P; Arrillaga-Romany IC; Eichler A; Forst DA; Gerstner E; Jordan JT; Ly I; Plotkin SR; Wang N; Martinez-Lage M; Winter SF; Tonn JC; Rejeski K; von Baumgarten L; Cahill DP; Nahed BV; Shankar GM; Abramson JS; Barnes JA; El-Jawahri A; Hochberg EP; Johnson PC; Soumerai JD; Takvorian RW; Chen YB; Frigault MJ; Dietrich J
Neuro Oncol; 2023 Dec; 25(12):2239-2249. PubMed ID: 37402650
[TBL] [Abstract][Full Text] [Related]
23. Chimeric antigen receptor T-cell therapy following autologous transplantation for secondary central nervous system lymphoma: A case report.
Yagi Y; Kanemasa Y; Ohigashi A; Morita Y; Tamura T; Nakamura S; Otsuka Y; Kishida Y; Kageyama A; Shimizuguchi T; Toya T; Shimizu H; Najima Y; Kobayashi T; Haraguchi K; Doki N; Okuyama Y; Omuro Y; Shimoyama T
Medicine (Baltimore); 2021 Nov; 100(44):e27733. PubMed ID: 34871273
[TBL] [Abstract][Full Text] [Related]
24. Safety evaluation of axicabtagene ciloleucel for relapsed or refractory large B-cell lymphoma.
Nath K; Wudhikarn K; Alarcon Tomas A; Perales MA
Expert Opin Drug Saf; 2023 Jan; 22(1):5-15. PubMed ID: 36737060
[TBL] [Abstract][Full Text] [Related]
25. Lisocabtagene maraleucel for patients with relapsed or refractory large B-cell lymphomas (TRANSCEND NHL 001): a multicentre seamless design study.
Abramson JS; Palomba ML; Gordon LI; Lunning MA; Wang M; Arnason J; Mehta A; Purev E; Maloney DG; Andreadis C; Sehgal A; Solomon SR; Ghosh N; Albertson TM; Garcia J; Kostic A; Mallaney M; Ogasawara K; Newhall K; Kim Y; Li D; Siddiqi T
Lancet; 2020 Sep; 396(10254):839-852. PubMed ID: 32888407
[TBL] [Abstract][Full Text] [Related]
26. Efficacy of CD19 directed therapies in patients with relapsed or refractory large b-cell lymphoma relapsing after CD19 directed chimeric antigen receptor T-cell therapy.
Iqbal M; Jagadeesh D; Chavez J; Khurana A; Rosenthal A; Craver E; Epperla N; Li Z; Isufi I; Awan FT; Dholaria BR; Maakaron JE; Sandoval-Sus JD; Mishra R; Saha A; Annunzio K; Bhaskar ST; Sumransub N; Fijalka A; Ivanov SA; Lin Y; Kharfan-Dabaja MA
Bone Marrow Transplant; 2024 Feb; 59(2):211-216. PubMed ID: 37973893
[TBL] [Abstract][Full Text] [Related]
27. Decitabine-primed tandem CD19/CD22 CAR-T therapy in relapsed/refractory diffuse large B-cell lymphoma patients.
Qu C; Zou R; Wang P; Zhu Q; Kang L; Ping N; Xia F; Liu H; Kong D; Yu L; Wu D; Jin Z
Front Immunol; 2022; 13():969660. PubMed ID: 36059523
[TBL] [Abstract][Full Text] [Related]
28. Outcomes of CD19-Directed Chimeric Antigen Receptor T Cell Therapy for Transformed Nonfollicular Lymphoma.
Dong N; Rubio Lopes-Garcia L; Viñal D; Bachmeier C; Shah BD; Nishihori T; Khimani F; Davila ML; Lazaryan A; Pinilla-Ibarz J; Locke FL; Jain MD; Chavez JC
Transplant Cell Ther; 2023 Jun; 29(6):349.e1-349.e8. PubMed ID: 36878427
[TBL] [Abstract][Full Text] [Related]
29. Efficacy and safety of chimeric antigen receptor T cell immunotherapy in B-cell non-Hodgkin lymphoma: a systematic review and meta-analysis.
Wang N; Meng Y; Wu Y; He J; Liu F
Immunotherapy; 2021 Mar; 13(4):345-357. PubMed ID: 33406914
[No Abstract] [Full Text] [Related]
30. Efficacy and Safety of Dual-Targeting Chimeric Antigen Receptor-T Therapy for Relapsed or Refractory B Cell Lymphoid Malignancies: A Systematic Review and Meta-Analysis.
Yu M; Zhang Q; Kong F; Qi L; Pu Y; Qiu L; Wang J; Li F
Hum Gene Ther; 2023 Mar; 34(5-6):192-202. PubMed ID: 36734417
[TBL] [Abstract][Full Text] [Related]
31. Systematic Review and Meta-analysis of CD19-Specific CAR-T Cell Therapy in Relapsed/Refractory Acute Lymphoblastic Leukemia in the Pediatric and Young Adult Population: Safety and Efficacy Outcomes.
Aamir S; Anwar MY; Khalid F; Khan SI; Ali MA; Khattak ZE
Clin Lymphoma Myeloma Leuk; 2021 Apr; 21(4):e334-e347. PubMed ID: 33573914
[TBL] [Abstract][Full Text] [Related]
32. Clinical Presentation, Risk Factors, and Outcomes of Immune Effector Cell-Associated Neurotoxicity Syndrome Following Chimeric Antigen Receptor T Cell Therapy: A Systematic Review.
Grant SJ; Grimshaw AA; Silberstein J; Murdaugh D; Wildes TM; Rosko AE; Giri S
Transplant Cell Ther; 2022 Jun; 28(6):294-302. PubMed ID: 35288347
[TBL] [Abstract][Full Text] [Related]
33. Clinical efficacy and safety of chimeric antigen receptor T-cell therapy for mantle cell lymphoma with secondary central nervous system involvement.
Ryan CE; Zon RL; Redd R; Fisher DC; Shouval R; Kumar A; Crombie JL; Sadrzadeh H; Kim AI; Nayak L; Chukwueke UN; Jacobson CA; Frigault MJ; Palomba ML; Armand P; Epstein-Peterson Z; Merryman RW
Br J Haematol; 2023 Dec; 203(5):774-780. PubMed ID: 37584155
[TBL] [Abstract][Full Text] [Related]
34. Long-term efficacy of CAR-T cell therapy for patients with relapsed/refractory B cell non-Hodgkin lymphoma.
Fu S; Hu Y; Huang H
Zhejiang Da Xue Xue Bao Yi Xue Ban; 2022 Apr; 51(2):167-174. PubMed ID: 36161292
[TBL] [Abstract][Full Text] [Related]
35. Sequential different B-cell antigen-targeted CAR T-cell therapy for pediatric refractory/relapsed Burkitt lymphoma.
Liu Y; Deng B; Hu B; Zhang W; Zhu Q; Liu Y; Wang S; Zhang P; Yang Y; Yang J; Zheng Q; Yu X; Gao Z; Zhou C; Han W; Yang J; Jin L; Tong C; Chang AH; Zhang Y
Blood Adv; 2022 Feb; 6(3):717-730. PubMed ID: 34521107
[TBL] [Abstract][Full Text] [Related]
36. Outcomes of CD19-Targeted Chimeric Antigen Receptor T Cell Therapy for Patients with Reduced Renal Function Including Dialysis.
Wood AC; Perez AP; Arciola B; Patel K; Johnson G; DiMaggio E; Bachmeier CA; Reid K; Carallo S; Vargas MH; Faramand R; Chavez JC; Shah B; Gaballa S; Khimani F; Elmariah H; Nishihori T; Lazaryan A; Freeman C; Davila ML; Locke FL; Mhaskar R; Bassil C; Jain MD
Transplant Cell Ther; 2022 Dec; 28(12):829.e1-829.e8. PubMed ID: 36174934
[TBL] [Abstract][Full Text] [Related]
37. Recent Bendamustine Treatment Before Apheresis Has a Negative Impact on Outcomes in Patients With Large B-Cell Lymphoma Receiving Chimeric Antigen Receptor T-Cell Therapy.
Iacoboni G; Navarro V; Martín-López AÁ; Rejeski K; Kwon M; Jalowiec KA; Amat P; Reguera-Ortega JL; Gallur L; Blumenberg V; Gutiérrez-Herrero S; Roddie C; Benzaquén A; Delgado-Serrano J; Sánchez-Salinas MA; Bailén R; Carpio C; López-Corral L; Hernani R; Bastos M; O'Reilly M; Martín-Martín L; Subklewe M; Barba P
J Clin Oncol; 2024 Jan; 42(2):205-217. PubMed ID: 37874957
[TBL] [Abstract][Full Text] [Related]
38. Phase 2 results of lisocabtagene maraleucel in Japanese patients with relapsed/refractory aggressive B-cell non-Hodgkin lymphoma.
Makita S; Yamamoto G; Maruyama D; Asano-Mori Y; Kaji D; Ananthakrishnan R; Ogasawara K; Stepan L; Schusterbauer C; Rettby N; Hasskarl J; Izutsu K
Cancer Med; 2022 Dec; 11(24):4889-4899. PubMed ID: 35619325
[TBL] [Abstract][Full Text] [Related]
39. [Efficacy and safety analysis of the zanubrutinib-based bridging regimen in chimeric antigen receptor T-cell therapy for relapsed/refractory diffuse large B-cell lymphoma].
Lu Y; Liu H; Ye SG; Zhou LL; Luo X; Dang XY; Yuan XG; Qian WB; Liang AB; Li P
Zhonghua Xue Ye Xue Za Zhi; 2023 Oct; 44(10):813-819. PubMed ID: 38049332
[No Abstract] [Full Text] [Related]
40. The impact of bridging therapy prior to CD19-directed chimeric antigen receptor T-cell therapy in patients with large B-cell lymphoma.
Lutfi F; Holtzman NG; Kansagra AJ; Mustafa Ali M; Bukhari A; Yan J; Samanta S; Gottlieb D; Kim DW; Matsumoto LR; Gahres N; Ruehle K; Lee ST; Law JY; Kocoglu MH; Atanackovic D; Yared JA; Hardy NM; Molitoris J; Mohindra P; Rapoport AP; Dahiya S
Br J Haematol; 2021 Nov; 195(3):405-412. PubMed ID: 34500492
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
